Chelsea Johnson, APRN
Psychiatric/Mental Health · Grand Island, NENPI 1194489575
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 407 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 26.4% of the total. 2025 is the largest year on record at $1,587, 7.1 times the $224 reported in 2021.
Across 407 payments — averaging $13.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$820
- Alkermes, Inc.$719
- Teva Pharmaceuticals USA, Inc.$602
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$316
- Lundbeck LLC$285
- plus $1K from 13 others
What the payments were for
- Food & beverage$5,454100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 132 | $1,441 |
| Otsuka America Pharmaceutical, Inc. | 50 | $820 |
| Alkermes, Inc. | 65 | $719 |
| Teva Pharmaceuticals USA, Inc. | 47 | $602 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $316 |
| Lundbeck LLC | 21 | $285 |
| Neurocrine Biosciences, Inc. | 17 | $278 |
| Axsome Therapeutics, Inc. | 8 | $221 |
| Johnson & Johnson | 9 | $163 |
| E.r. Squibb & Sons, L.L.C. | 15 | $142 |
| Indivior Inc. | 5 | $96 |
| Idorsia Pharmaceuticals US Inc | 5 | $70 |
| CSL Behring | 2 | $65 |
| Corium, LLC | 5 | $65 |
| Sunovion Pharmaceuticals Inc. | 4 | $63 |
| Harmony Biosciences LLC | 3 | $45 |
| Vanda Pharmaceuticals Inc. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Merck | 1 | $14 |
How this compares
$5,462 in reported general payments places this provider in the 85th percentile of 255 psychiatric/mental health providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 57 | $195,838 |
| IngrezzaValbenazine Tosylate | 18 | $147,996 |
| VraylarCariprazine Hcl | 46 | $67,068 |
| RexultiBrexpiprazole | 20 | $31,257 |
| Aripiprazole | 33 | $4,583 |
| Lisdexamfetamine Dimesylate | 17 | $3,322 |
| Asenapine Maleate | 17 | $2,800 |
| Paliperidone ErPaliperidone | 14 | $1,876 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 21 | $1,674 |
| Buspirone Hcl | 94 | $1,619 |
| Atomoxetine Hcl | 18 | $1,523 |
| Trazodone Hcl | 102 | $1,003 |
| Quetiapine Fumarate | 60 | $888 |
| Lamotrigine | 43 | $817 |
| Olanzapine | 42 | $791 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $163 | $195,83857 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $278 | $147,99618 claims |
| AbbVieVraylar | $1,441 | $67,06846 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $820 | $31,25720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 255 psychiatric/mental health providers in Nebraska.
Other psychiatric/mental health in Grand Island
- Sherry KropatschGrand Island$11K
- Ashley KennedyGrand Island$6K
- Linda BerryGrand Island$5K
- Jennifer MurrayGrand Island$4K
- Kylene SchroerGrand Island$3K
- Dacia OakesonHastings$32K
- Margaret Emersonla Vista$30K
- Janelle HillOmaha$24K
- Kristi BoseOmaha$13K
- Robert LundholmOmaha$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.